Pemigatinib for advanced gut cancers with FGFR gene changes
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests pemigatinib, a targeted medicine, for advanced or metastatic gastrointestinal (GI) cancers that have specific FGFR1–3 gene changes. It’s for people whose cancer has grown despite prior standard treatment, and who may benefit if their tumor has the right genetic change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- You have advanced, recurring, or metastatic GI cancer that can’t be removed with surgery.
- Your tumor has FGFR1–3 changes found on lab testing (such as gene mutation, fusion, or extra copies).
- Your cancer has gotten worse after prior standard treatment.
- You have at least one measurable tumor spot that doctors can track on scans.
- You can do usual daily activities fairly well (ECOG performance status 0 to 1) and have enough blood/organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.